Veterinary Vaccines Market - Global Forecast To 2029
商品番号 : SMB-31784
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年1月 |
| ページ数 | 407 |
| 図表数 | 520 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The veterinary vaccines market is projected to reach USD 13.33 billion by 2029, from USD 9.39 billion in 2024, at a CAGR of 6.1%.” during the forecast period.
動物用ワクチン市場は、予測期間中CAGR 6.1%で、2024年の93億9,000万米ドルから2029年までに133億3,000万米ドルに達すると予測されています。
The growing awareness of animal health, along with the rising pet population and pet ownership, is driving the adoption of veterinary vaccines. Government initiatives aimed at improving animal health and the increasing uptake of pet insurance policies are also contributing to this trend. In major markets like North America and Europe, many pet owners are purchasing pet insurance due to the significant rise in pet care spending in recent years. Additionally, the focus on developing new and advanced vaccine products, combined with the growing adoption of veterinary vaccines in emerging economies, is expected to further support market growth. However, the high costs associated with vaccines may pose a challenge to the veterinary vaccines market’s expansion.
“The livestock vaccines segment of veterinary vaccines market to register highest share during the forecast period.”
Based on type, the livestock vaccines segment accounted for the largest share. As livestock animals are owned for the production of food, such as meat and dairy products. As global demand for animal derived food increases and livestock farming intensifies to meet the nutritional needs of an expanding population, there is a greater emphasis on maintaining animal health, preventing disease outbreaks, and improving productivity. Additionally, government regulations, rising awareness about animal health, and growing demand for safer, disease-free food products are driving the adoption of livestock vaccines, further contributing to their dominant share in the market.
“The intramuscular segment to capture the largest market share of veterinary vaccines market.”
Based on route of administration, intramuscular vaccines hold a higher share in the veterinary vaccines market due to their effectiveness and widespread use. Compared to conventional methods of administration like subcutaneous or oral vaccines, this kind of vaccine is delivered directly into the muscle, enabling a faster and more powerful immune response. Because of their ability to produce long-lasting immunity, intramuscular vaccines are frequently used to treat a range of conditions, including bacterial, viral, and parasite infections. The increased market share of intramuscular vaccines is partly a result of their shown efficacy, simplicity of use, and veterinarians’ inclination for this approach in both individual pet care and large-scale farming.
“Asia pacific accounted for the fastest growing region of the veterinary vaccines market by region.”
The global veterinary vaccines market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing market for veterinary vaccines. The increased ownership of pets is a major factor driving the need for veterinary care and vaccinations, particularly in economies like China, India, and Japan. Pet owners are also being encouraged to invest in vaccinations as a result of the region’s increasing awareness of animal health and preventative measures. Growing focus on livestock health, better veterinary facilities, and economic expansion all contribute significantly to the market’s growth. Governments and organizations have backed animal health initiatives, and more consumers are looking for improved pet healthcare as disposable incomes rise. The Asia Pacific region is becoming a significant growth engine for the veterinary vaccines market due to this confluence of variables.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–35%, Tier 2–40%, and Tier 3– 25%
- By Designation: Directors–25%, Managers–50% and Others–25%
- By Region: North America–35%, Europe–30%, Asia Pacific–15% and RoW–20%
The major players operating in the veterinary vaccines market market are Zoetis(US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), Virbac (France), Ceva (France), Phibro Animal Health Corporation (US), Hester Biosciences Limited (India), Neogen Corporation (US), HIPRA (Spain), Biogénesis Bagó (Argentina), Tianjin Ringpu BioTechnology Co., Ltd. (China), China Animal Husbandry Industry Co., LTD. (China), Jinyu Bio-technology Co., Ltd. (China), and Vaxxinova International B.V.(Netherlands).
Research Coverage
This report studies the veterinary vaccines market based on type, disease, technology, route of administration and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
Analysis of Key divers (increased companion animal population and pet ownership, growing incidence of infectious disease, government initiatives to improve animal health), restraints (high cost associated with vaccines), Opportunities (emerging markets, technological advancement and developments) , Challenge (limited awareness and shortage of veterinarians, stringent regulatory requirements)
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the veterinary vaccines market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the veterinary vaccines market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the veterinary vaccines market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
Table of Contents
1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.3 STUDY SCOPE 34
1.3.1 MARKET SEGMENTATION & GEOGRAPHICAL SPREAD 34
1.3.2 INCLUSIONS & EXCLUSIONS 35
1.3.3 YEARS CONSIDERED 36
1.3.4 CURRENCY CONSIDERED 36
1.4 STAKEHOLDERS 36
1.5 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
2.1.1 SECONDARY DATA 39
2.1.1.1 Key secondary sources 39
2.1.1.2 Key data from secondary sources 40
2.1.2 PRIMARY DATA 40
2.1.2.1 Key primary sources 40
2.1.2.2 Objectives of primary research 41
2.1.2.3 Key data from primary sources 41
2.1.2.4 Key industry insights 42
2.1.2.5 Breakdown of primaries 42
2.2 MARKET SIZE ESTIMATION 44
2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 44
2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 46
2.2.3 TOP-DOWN APPROACH 48
2.3 DATA TRIANGULATION 49
2.4 MARKET SHARE ANALYSIS 50
2.5 STUDY ASSUMPTIONS 50
2.6 RISK ASSESSMENT 50
2.7 RESEARCH LIMITATIONS 51
2.7.1 METHODOLOGY-RELATED LIMITATIONS 51
2.7.2 SCOPE-RELATED LIMITATIONS 51
3 EXECUTIVE SUMMARY 52
4 PREMIUM INSIGHTS 57
4.1 VETERINARY VACCINES MARKET OVERVIEW 57
4.2 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY AND COUNTRY (2023) 58
4.3 VETERINARY VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
5.2.1 DRIVERS 61
5.2.1.1 Rise in companion animal population and pet ownership 61
5.2.1.2 Increasing incidence of infectious zoonotic diseases 62
5.2.1.3 Favorable initiatives by government agencies and
animal associations 62
5.2.1.4 Growing demand for animal-derived food products 63
5.2.1.5 Increased adoption of pet insurance and high
animal health expenditure 65
5.2.2 RESTRAINTS 66
5.2.2.1 High cost of vaccine development 66
5.2.3 OPPORTUNITIES 66
5.2.3.1 Technological advancements for veterinary vaccine development 66
5.2.3.2 Untapped growth potential in emerging economies 67
5.2.4 CHALLENGES 67
5.2.4.1 Limited awareness about animal vaccines and shortage of trained veterinarians in low-income countries 67
5.2.4.2 Stringent regulatory requirements for licensing veterinary vaccines 68
5.3 INDUSTRY TRENDS 68
5.4 TECHNOLOGY ANALYSIS 69
5.4.1 KEY TECHNOLOGIES 69
5.4.1.1 Recombinant DNA technology 69
5.4.1.2 mRNA-based vaccines 69
5.4.2 COMPLEMENTARY TECHNOLOGIES 70
5.4.2.1 Vaccine adjuvant technology 70
5.4.2.2 Needle-free and microneedle technology 70
5.4.3 ADJACENT TECHNOLOGIES 70
5.4.3.1 Genome editing technology 70
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 71
5.6 SUPPLY CHAIN ANALYSIS 71
5.7 VALUE CHAIN ANALYSIS 73
5.8 TRADE ANALYSIS 74
5.8.1 IMPORT DATA FOR HS CODE 300242 74
5.8.2 EXPORT DATA FOR HS CODE 300230 75
5.9 PORTER’S FIVE FORCES ANALYSIS 75
5.9.1 THREAT OF NEW ENTRANTS 77
5.9.2 THREAT OF SUBSTITUTES 77
5.9.3 BARGAINING POWER OF SUPPLIERS 77
5.9.4 BARGAINING POWER OF BUYERS 77
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 78
5.10 KEY STAKEHOLDERS & BUYING CRITERIA 78
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 78
5.10.2 KEY BUYING CRITERIA 79
5.11 REGULATORY ANALYSIS 80
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
5.11.2 REGULATORY FRAMEWORK 83
5.11.2.1 North America 84
5.11.2.1.1 US 84
5.11.2.2 Europe 84
5.11.2.3 Rest of the World 85
5.11.2.3.1 China 85
5.11.2.3.2 Brazil 85
5.11.2.3.3 Australia 85
5.12 PATENT ANALYSIS 86
5.12.1 JURISDICTION AND TOP APPLICANT ANALYSIS 86
5.13 PRICING ANALYSIS 89
5.13.1 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES,
BY KEY PLAYER, 2021–2023 89
5.13.2 AVERAGE SELLING PRICE TREND, BY REGION, 2021–2023 91
5.14 KEY CONFERENCES & EVENTS, 2024–2026 92
5.15 ECOSYSTEM ANALYSIS 94
5.16 CASE STUDY ANALYSIS 95
5.17 REIMBURSEMENT ANALYSIS 97
5.18 UNMET NEEDS/END-USER EXPECTATIONS 97
5.19 IMPACT OF AI/GEN AI ON VETERINARY VACCINES MARKET 98
5.20 INVESTMENT & FUNDING SCENARIO 98
5.21 PIPELINE ANALYSIS 99
6 VETERINARY VACCINES MARKET, BY TYPE 101
6.1 INTRODUCTION 102
6.2 LIVESTOCK VACCINES 103
6.2.1 BOVINE VACCINES 105
6.2.1.1 Increasing demand for meat and milk to drive market 105
6.2.2 SMALL RUMINANT VACCINES 107
6.2.2.1 Increased livestock population and favorable government initiatives to propel market growth 107
6.3 PORCINE VACCINES 109
6.3.1 GROWING AWARENESS ABOUT ANIMAL VACCINATION TO
SUPPORT MARKET GROWTH 109
6.4 POULTRY VACCINES 111
6.4.1 HIGH NEED FOR PROTEIN IN DAILY DIET TO AUGMENT MARKET GROWTH 111
6.5 COMPANION ANIMAL VACCINES 113
6.5.1 CANINE VACCINES 115
6.5.1.1 Increasing number of pet dogs and growing prevalence of zoonotic diseases to spur market growth 115
6.5.2 FELINE VACCINES 117
6.5.2.1 Rising adoption of cats and growing need for better veterinary care to boost market growth 117
6.6 AQUACULTURE VACCINES 119
6.6.1 INCREASED POPULARITY OF COMMERCIAL FISH FARMING TO
FUEL MARKET GROWTH 119
6.7 OTHER VETERINARY VACCINES 120
7 VETERINARY VACCINES MARKET, BY DISEASE 122
7.1 INTRODUCTION 123
7.2 LIVESTOCK DISEASES 123
7.2.1 BOVINE DISEASES 126
7.2.1.1 Favorable government programs and increased awareness about animal health in emerging economies to aid market growth 126
7.2.2 SMALL RUMINANT DISEASES 128
7.2.2.1 New vaccine formulations and improved delivery methods to propel vaccine demand for small ruminants 128
7.3 PORCINE DISEASES 130
7.3.1 INCREASED FOCUS ON LARGE-SCALE INDUSTRIAL BREEDING OF
PIGS TO AID MARKET GROWTH 130
7.4 POULTRY DISEASES 132
7.4.1 ONGOING RISK OF AVIAN INFLUENZA OUTBREAKS TO SPUR
NEED FOR POULTRY VACCINES 132
7.5 COMPANION ANIMAL DISEASES 134
7.5.1 CANINE DISEASES 136
7.5.1.1 Rise in pet ownership in emerging economies to boost market growth 136
7.5.2 FELINE DISEASES 138
7.5.2.1 Rise in cat population in urban areas to drive demand for feline disease management programs 138
7.6 AQUACULTURE DISEASES 140
7.6.1 NEED FOR PREVENTIVE HEALTHCARE AND BIOSECURITY TO
SUPPORT MARKET GROWTH 140
7.7 OTHER VETERINARY DISEASES 142
8 VETERINARY VACCINES MARKET, BY TECHNOLOGY 144
8.1 INTRODUCTION 145
8.2 LIVE ATTENUATED VACCINES 145
8.2.1 EASE OF ADMINISTRATION AND LONG-TERM IMMUNITY TO
SUPPORT MARKET GROWTH 145
8.3 INACTIVATED VACCINES 147
8.3.1 NEED TO DEVELOP ARTIFICIAL IMMUNITY FROM NON-LIVING
PATHOGENS TO DRIVE MARKET 147
8.4 TOXOID VACCINES 149
8.4.1 TOXOID VACCINES TO STIMULATE IMMUNE SYSTEM AND PROTECT ANIMALS FROM BACTERIAL TOXINS 149
8.5 RECOMBINANT VACCINES 151
8.5.1 BETTER STABILITY, HIGHER SAFETY, AND NO POST-VACCINATION REACTIONS TO SUPPORT VACCINE ADOPTION 151
8.6 OTHER VACCINE TECHNOLOGIES 153
9 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION 155
9.1 INTRODUCTION 156
9.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION 158
9.2.1 EASE OF ADMINISTRATION, REDUCED PAIN, AND LOWER RISK OF TISSUE DAMAGE TO AID MARKET GROWTH 158
9.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION 161
9.3.1 BETTER IMMUNE RESPONSE AND LOWER RATE OF INJECTION-SITE REACTIONS TO AUGMENT MARKET GROWTH 161
9.4 ORAL ROUTE OF ADMINISTRATION 163
9.4.1 COST-EFFECTIVENESS, INCREASED SAFETY, AND HIGH PATIENT ACCEPTABILITY TO SUPPORT MARKET GROWTH 163
9.5 INTRANASAL/SPRAY ROUTE OF ADMINISTRATION 165
9.5.1 COST-EFFECTIVENESS AND RAPID ABSORPTION OF MEDICINE TO AID IN MASS VACCINATION 165
9.6 INTRAOCULAR ROUTE OF ADMINISTRATION 167
9.6.1 SIMPLE ADMINISTRATION OF VACCINES IN LARGE-SCALE FARMING OPERATIONS TO AID MARKET GROWTH 167
9.7 OTHER ROUTES OF ADMINISTRATION 169
10 VETERINARY VACCINES MARKET, BY END USER 171
10.1 INTRODUCTION 172
10.2 VETERINARY HOSPITALS 172
10.2.1 GROWING AWARENESS ABOUT ANIMAL HEALTH AND INCREASING VETERINARY EXPENDITURE BY PET OWNERS TO DRIVE MARKET 172
10.3 VETERINARY CLINICS 174
10.3.1 RISING NUMBER OF PET VISITS TO PRIVATE CLINICS TO
SPUR MARKET GROWTH 174
10.4 OTHER END USERS 176
11 VETERINARY VACCINES MARKET, BY REGION 177
11.1 INTRODUCTION 178
11.2 ASIA PACIFIC 182
11.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 187
11.2.2 CHINA 189
11.2.2.1 Increasing companion animal population and growing incidence of zoonotic diseases to drive market 189
11.2.3 JAPAN 193
11.2.3.1 High consumption of animal-derived products and increased pet health expenditure to propel market growth 193
11.2.4 INDIA 197
11.2.4.1 Growth in poultry industry and high demand for dairy products to augment market growth 197
11.2.5 AUSTRALIA 202
11.2.5.1 Increase in per capita income and rise in meat consumption to
aid market growth 202
11.2.6 SOUTH KOREA 206
11.2.6.1 High demand for animal protein and favorable government subsidies for meat production to spur market growth 206
11.2.7 NEW ZEALAND 210
11.2.7.1 Favorable government initiatives and increased incidence of livestock diseases to boost market growth 210
11.2.8 REST OF ASIA PACIFIC 214
11.3 NORTH AMERICA 218
11.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 223
11.3.2 US 224
11.3.2.1 US to dominate North American veterinary vaccines market
during forecast period 224
11.3.3 CANADA 228
11.3.3.1 Rising pet ownership and increasing chicken consumption to
drive demand for veterinary vaccines 228
11.4 EUROPE 232
11.4.1 MACROECONOMIC OUTLOOK FOR EUROPE 237
11.4.2 GERMANY 238
11.4.2.1 Increased poultry consumption and high pet healthcare expenditure to drive market 238
11.4.3 UK 242
11.4.3.1 Rising adoption of pets to augment market growth 242
11.4.4 FRANCE 246
11.4.4.1 Rising companion animal and livestock population to
boost market growth 246
11.4.5 ITALY 250
11.4.5.1 Better availability of pet products through large-scale outlets to augment market growth 250
11.4.6 SPAIN 254
11.4.6.1 Increase in veterinary practices and willingness to spend on animal healthcare to drive market 254
11.4.7 NETHERLANDS 258
11.4.7.1 High demand for meat and increased pressure on sustainable farming practices to fuel market growth 258
11.4.8 REST OF EUROPE 262
11.5 LATIN AMERICA 266
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 270
11.5.2 BRAZIL 271
11.5.2.1 Well-established livestock industry to promote market growth 271
11.5.3 MEXICO 275
11.5.3.1 Focus on pork and poultry meat production to fuel market growth 275
11.5.4 REST OF LATIN AMERICA 279
11.6 MIDDLE EAST & AFRICA 282
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 287
11.6.2 GCC COUNTRIES 288
11.6.2.1 Kingdom of Saudi Arabia 292
11.6.2.1.1 Favorable government initiatives for better animal health infrastructure to propel market growth 292
11.6.2.2 UAE 296
11.6.2.2.1 Favorable government initiatives to safeguard national livestock population and support sustainable agriculture 296
11.6.2.3 Rest of GCC countries 300
11.6.3 REST OF MIDDLE EAST & AFRICA 304
12 COMPETITIVE LANDSCAPE 308
12.1 INTRODUCTION 308
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 308
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 308
12.3 REVENUE ANALYSIS, 2019–2023 310
12.4 MARKET SHARE ANALYSIS, 2023 311
12.4.1 RANKING OF KEY MARKET PLAYERS, 2O23 313
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 314
12.5.1 STARS 314
12.5.2 EMERGING LEADERS 314
12.5.3 PERVASIVE PLAYERS 314
12.5.4 PARTICIPANTS 314
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 316
12.5.5.1 Company footprint 316
12.5.5.2 Region footprint 317
12.5.5.3 Type footprint 318
12.5.5.4 Disease footprint 319
12.5.5.5 Technology footprint 320
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 321
12.6.1 PROGRESSIVE COMPANIES 321
12.6.2 RESPONSIVE COMPANIES 321
12.6.3 DYNAMIC COMPANIES 321
12.6.4 STARTING BLOCKS 321
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 323
12.7 BRAND/PRODUCT COMPARISON 324
12.8 R&D EXPENDITURE OF KEY PLAYERS 325
12.9 COMPANY VALUATION & FINANCIAL METRICS 325
12.9.1 FINANCIAL METRICS 325
12.9.2 COMPANY VALUATION 326
12.10 COMPETITIVE SCENARIO 326
12.10.1 PRODUCT LAUNCHES & APPROVALS 326
12.10.2 DEALS 327
12.10.3 EXPANSIONS 328
12.10.4 OTHER DEVELOPMENTS 328
13 COMPANY PROFILES 329
13.1 KEY PLAYERS 329
13.1.1 MERCK & CO., INC. 329
13.1.1.1 Business overview 329
13.1.1.2 Products offered 330
13.1.1.3 Recent developments 333
13.1.1.3.1 Product launches & approvals 333
13.1.1.3.2 Deals 334
13.1.1.3.3 Expansions 334
13.1.1.3.4 Other developments 335
13.1.1.4 MnM view 335
13.1.1.4.1 Right to win 335
13.1.1.4.2 Strategic choices 335
13.1.1.4.3 Weaknesses & competitive threats 335
13.1.2 ZOETIS 336
13.1.2.1 Business overview 336
13.1.2.2 Products offered 337
13.1.2.3 Recent developments 339
13.1.2.3.1 Product launches 339
13.1.2.3.2 Deals 339
13.1.2.3.3 Expansions 339
13.1.2.3.4 Other developments 340
13.1.2.4 MnM view 340
13.1.2.4.1 Right to win 340
13.1.2.4.2 Strategic choices 340
13.1.2.4.3 Weaknesses & competitive threats 340
13.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 341
13.1.3.1 Business overview 341
13.1.3.2 Products offered 342
13.1.3.3 Recent developments 343
13.1.3.3.1 Product launches 343
13.1.3.3.2 Expansions 344
13.1.3.4 MnM view 344
13.1.3.4.1 Right to win 344
13.1.3.4.2 Strategic choices 344
13.1.3.4.3 Weaknesses & competitive threats 345
13.1.4 ELANCO 346
13.1.4.1 Business overview 346
13.1.4.2 Products offered 348
13.1.4.3 Recent developments 349
13.1.4.3.1 Deals 349
13.1.5 CEVA 350
13.1.5.1 Business overview 350
13.1.5.2 Products offered 350
13.1.5.3 Recent developments 352
13.1.5.3.1 Deals 352
13.1.5.3.2 Expansions 353
13.1.6 VIRBAC 354
13.1.6.1 Business overview 354
13.1.6.2 Products offered 355
13.1.6.3 Recent developments 356
13.1.6.3.1 Product launches 356
13.1.6.3.2 Deals 357
13.1.6.3.3 Expansions 357
13.1.6.3.4 Other developments 358
13.1.7 PHIBRO ANIMAL HEALTH CORPORATION 359
13.1.7.1 Business overview 359
13.1.7.2 Products offered 360
13.1.8 HESTER BIOSCIENCES LIMITED 362
13.1.8.1 Business overview 362
13.1.8.2 Products offered 363
13.1.8.3 Recent developments 365
13.1.8.3.1 Deals 365
13.1.9 NEOGEN CORPORATION 366
13.1.9.1 Business overview 366
13.1.9.2 Products offered 367
13.1.9.3 Recent developments 368
13.1.9.3.1 Deals 368
13.1.10 HIPRA 369
13.1.10.1 Business overview 369
13.1.10.2 Products offered 369
13.1.10.3 Recent developments 372
13.1.10.3.1 Product launches 372
13.1.11 BIOGÉNESIS BAGÓ 373
13.1.11.1 Business overview 373
13.1.11.2 Products offered 373
13.1.11.3 Recent developments 374
13.1.11.3.1 Expansions 374
13.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD. 375
13.1.12.1 Business overview 375
13.1.12.2 Products offered 376
13.1.12.3 Recent developments 378
13.1.12.3.1 Deals 378
13.1.13 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. 379
13.1.13.1 Business overview 379
13.1.13.2 Products offered 379
13.1.14 JINYU BIO-TECHNOLOGY CO., LTD. 381
13.1.14.1 Business overview 381
13.1.14.2 Products offered 382
13.1.14.3 Recent developments 384
13.1.14.3.1 Product approvals 384
13.1.15 VAXXINOVA INTERNATIONAL B.V. 385
13.1.15.1 Business overview 385
13.1.15.2 Products offered 386
13.1.15.3 Recent developments 387
13.1.15.3.1 Product approvals 387
13.1.15.3.2 Expansions 387
13.2 OTHER COMPANIES 388
13.2.1 ENDOVAC ANIMAL HEALTH 388
13.2.2 BRILLIANT BIO PHARMA 389
13.2.3 APTIMMUNE 390
13.2.4 INDIAN IMMUNOLOGICALS LTD. 391
13.2.5 TORIGEN PHARMACEUTICALS INC. 392
13.2.6 INTAS PHARMACEUTICALS LTD. 392
13.2.7 OUROFINO ANIMAL HEALTH 393
13.2.8 BIOVAC LTD. 394
13.2.9 LABORATOIRE LCV 395
13.2.10 KYORITSU SEIYAKU CORPORATION 396
14 APPENDIX 397
14.1 DISCUSSION GUIDE 397
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 403
14.3 CUSTOMIZATION OPTIONS 405
14.4 RELATED REPORTS 405
14.5 AUTHOR DETAILS 406
LIST OF TABLES
TABLE 1 VETERINARY VACCINES MARKET: INCLUSIONS & EXCLUSIONS 35
TABLE 2 STANDARD CURRENCY CONVERSION RATES 36
TABLE 3 VETERINARY VACCINES MARKET: STUDY ASSUMPTIONS 50
TABLE 4 VETERINARY VACCINES MARKET: RISK ASSESSMENT ANALYSIS 50
TABLE 5 PET (DOGS AND CATS) OWNERSHIP IN US, 2024 61
TABLE 6 MAJOR OUTBREAKS OF ZOONOTIC DISEASES, 2022–2023 62
TABLE 7 PAST AND PROJECTED TRENDS IN CONSUMPTION OF MEAT AND
MILK IN DEVELOPED COUNTRIES 64
TABLE 8 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 64
TABLE 9 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS,
2020 VS. 2030 (THOUSAND METRIC TONS) 65
TABLE 10 KEY COMMERCIAL PRODUCTS USING RECOMBINANT DNA TECHNOLOGY 69
TABLE 11 IMPORT DATA FOR HS CODE 300230, BY COUNTRY,
2019–2023 (USD THOUSAND) 74
TABLE 12 EXPORT VALUE FOR HS CODE 300230, BY COUNTRY,
2019–2023 (USD THOUSAND) 75
TABLE 13 VETERINARY VACCINES MARKET: PORTER’S FIVE FORCES 75
TABLE 14 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF VETERINARY VACCINES, BY END USER 78
TABLE 15 KEY BUYING CRITERIA FOR END USERS 79
TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82
TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 83
TABLE 19 VETERINARY VACCINES MARKET: LIST OF GRANTED PATENTS, 2022–2023 88
TABLE 20 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES,
BY KEY PLAYER, 2021–2023 89
TABLE 21 AVERAGE SELLING PRICE TREND OF CANINE VACCINES (PER DOSE),
BY REGION, 2021–2023 91
TABLE 22 AVERAGE SELLING PRICE TREND OF LIVESTOCK VACCINES (PER DOSE)
BY REGION, 2021–2023 92
TABLE 23 VETERINARY VACCINES MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024–DECEMBER 2026 92
TABLE 24 VETERINARY VACCINES MARKET: ROLE IN ECOSYSTEM 95
TABLE 25 CASE STUDY 1: SUPPORTING INNOVATION IN LIVESTOCK VACCINES 95
TABLE 26 CASE STUDY 2: IMPACT OF A19 VACCINATION ON LIVESTOCK
HEALTH AND PRODUCTIVITY 96
TABLE 27 CASE STUDY 3: DEVELOPMENT OF CANINE VACCINES FOR VALLEY FEVER 96
TABLE 28 VETERINARY VACCINES MARKET: UNMET NEEDS/END-USER EXPECTATIONS 97
TABLE 29 VETERINARY VACCINES MARKET: PIPELINE ANALYSIS 99
TABLE 30 VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 102
TABLE 31 LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 103
TABLE 32 LIVESTOCK VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 33 COMMERCIAL BOVINE VACCINES BY KEY MANUFACTURERS 105
TABLE 34 BOVINE VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 35 COMMERCIAL SMALL RUMINANT VACCINES BY KEY MANUFACTURERS 107
TABLE 36 SMALL RUMINANT VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 37 COMMERCIAL PORCINE VACCINES BY KEY MANUFACTURERS 109
TABLE 38 PORCINE VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 39 COMMERCIAL POULTRY VACCINES BY KEY MANUFACTURERS 111
TABLE 40 POULTRY VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 41 COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 113
TABLE 42 COMPANION ANIMAL VACCINES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 114
TABLE 43 COMMERCIAL CANINE VACCINES BY KEY MANUFACTURERS 115
TABLE 44 CANINE VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 45 COMMERCIAL FELINE VACCINES BY KEY MANUFACTURERS 117
TABLE 46 FELINE VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 47 COMMERCIAL AQUACULTURE VACCINES BY KEY MANUFACTURERS 119
TABLE 48 AQUACULTURE VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 49 OTHER COMMERCIAL VETERINARY VACCINES BY KEY MANUFACTURERS 121
TABLE 50 OTHER VETERINARY VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 51 VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION) 123
TABLE 52 VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE,
2022–2029 (USD MILLION) 124
TABLE 53 VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY COUNTRY,
2022–2029 (USD MILLION) 125
TABLE 54 BOVINE DISEASES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 55 SMALL RUMINANT DISEASES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 56 VETERINARY VACCINES MARKET FOR PORCINE DISEASES, BY COUNTRY,
2022–2029 (USD MILLION) 131
TABLE 57 VETERINARY VACCINES MARKET FOR POULTRY DISEASES, BY COUNTRY,
2022–2029 (USD MILLION) 133
TABLE 58 VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 134
TABLE 59 VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 60 CANINE DISEASES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 61 FELINE DISEASES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 62 VETERINARY VACCINES MARKET FOR AQUACULTURE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 63 VETERINARY VACCINES MARKET FOR OTHER VETERINARY DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 64 VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 145
TABLE 65 COMMERCIALLY AVAILABLE KEY LIVE ATTENUATED VACCINES 146
TABLE 66 LIVE ATTENUATED VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 67 COMMERCIALLY AVAILABLE KEY INACTIVATED VACCINES 147
TABLE 68 INACTIVATED VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 69 COMMERCIALLY AVAILABLE KEY TOXOID VACCINES 149
TABLE 70 TOXOID VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 71 COMMERCIALLY AVAILABLE KEY RECOMBINANT VACCINES 151
TABLE 72 RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 73 COMMERCIALLY AVAILABLE OTHER KEY VACCINE TECHNOLOGIES 153
TABLE 74 OTHER VACCINE TECHNOLOGIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 154
TABLE 75 ROUTES OF ADMINISTRATION FOR MAJOR VETERINARY VACCINES, BY KEY PLAYER 156
TABLE 76 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 158
TABLE 77 COMMERCIALLY AVAILABLE VACCINES WITH SUBCUTANEOUS
ROUTE OF ADMINISTRATION 159
TABLE 78 VETERINARY VACCINES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 79 COMMERCIALLY AVAILABLE VACCINES WITH INTRAMUSCULAR
ROUTE OF ADMINISTRATION 161
TABLE 80 VETERINARY VACCINES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 81 COMMERCIALLY AVAILABLE VACCINES WITH ORAL ROUTE OF ADMINISTRATION 163
TABLE 82 VETERINARY VACCINES MARKET FOR ORAL ROUTE OF ADMINISTRATION,
BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 83 COMMERCIALLY AVAILABLE VACCINES WITH INTRANASAL/SPRAY
ROUTE OF ADMINISTRATION 165
TABLE 84 VETERINARY VACCINES MARKET FOR INTRANASAL/SPRAY ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 166
TABLE 85 COMMERCIALLY AVAILABLE VACCINES WITH INTRAOCULAR
ROUTE OF ADMINISTRATION 167
TABLE 86 VETERINARY VACCINES MARKET FOR INTRAOCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 168
TABLE 87 COMMERCIALLY AVAILABLE VACCINES WITH OTHER ROUTES OF ADMINISTRATION 169
TABLE 88 VETERINARY VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION,
BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 89 VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION) 172
TABLE 90 VETERINARY HOSPITALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 91 VETERINARY CLINICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 175
TABLE 92 OTHER END USERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 93 VETERINARY VACCINES MARKET, BY REGION, 2022–2029 (USD MILLION) 178
TABLE 94 PORCINE VACCINES MARKET, BY REGION, 2022–2029 (MILLION UNITS) 178
TABLE 95 POULTRY VACCINES MARKET, BY REGION, 2022–2029 (MILLION UNITS) 179
TABLE 96 BOVINE VACCINES MARKET, BY REGION, 2022–2029 (MILLION UNITS) 179
TABLE 97 SMALL RUMINANT VACCINES MARKET, BY REGION, 2022–2029 (MILLION UNITS) 180
TABLE 98 CANINE VACCINES MARKET, BY REGION, 2022–2029 (MILLION UNITS) 180
TABLE 99 FELINE VACCINES MARKET, BY REGION, 2022–2029 (MILLION UNITS) 181
TABLE 100 AQUACULTURE VACCINES MARKET, BY REGION, 2022–2029 (MILLION UNITS) 181
TABLE 101 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 184
TABLE 102 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 184
TABLE 104 ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 185
TABLE 105 ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 185
TABLE 106 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 185
TABLE 107 ASIA PACIFIC: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 108 ASIA PACIFIC: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 109 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 186
TABLE 111 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 187
TABLE 112 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 187
TABLE 113 NUMBER OF VETERINARIANS IN KEY ASIA PACIFIC COUNTRIES, 2022 189
TABLE 114 CHINA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 115 CHINA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 116 CHINA: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 190
TABLE 117 CHINA: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION) 191
TABLE 118 CHINA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 191
TABLE 119 CHINA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 191
TABLE 120 CHINA: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 192
TABLE 121 CHINA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 192
TABLE 122 CHINA: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 193
TABLE 123 JAPAN: PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2000 VS. 2030 (THOUSAND METRIC TONS) 194
TABLE 124 JAPAN: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 125 JAPAN: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 126 JAPAN: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 195
TABLE 127 JAPAN: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION) 195
TABLE 128 JAPAN: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 195
TABLE 129 JAPAN: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 196
TABLE 130 JAPAN: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 196
TABLE 131 JAPAN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 197
TABLE 132 JAPAN: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 197
TABLE 133 INDIA: PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2000 VS. 2030 (THOUSAND METRIC TONS) 198
TABLE 134 INDIA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 135 INDIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 136 INDIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 199
TABLE 137 INDIA: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION) 200
TABLE 138 INDIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 200
TABLE 139 INDIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 200
TABLE 140 INDIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 201
TABLE 141 INDIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 201
TABLE 142 INDIA: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 202
TABLE 143 AUSTRALIA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 144 AUSTRALIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 145 AUSTRALIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 203
TABLE 146 AUSTRALIA: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 204
TABLE 147 AUSTRALIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 148 AUSTRALIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 149 AUSTRALIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 205
TABLE 150 AUSTRALIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 205
TABLE 151 AUSTRALIA: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 206
TABLE 152 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 207
TABLE 153 SOUTH KOREA: LIVESTOCK VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 207
TABLE 154 SOUTH KOREA: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 207
TABLE 155 SOUTH KOREA: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 208
TABLE 156 SOUTH KOREA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 208
TABLE 157 SOUTH KOREA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 208
TABLE 158 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 209
TABLE 159 SOUTH KOREA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 209
TABLE 160 SOUTH KOREA: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 210
TABLE 161 NEW ZEALAND: VETERINARY VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 211
TABLE 162 NEW ZEALAND: LIVESTOCK VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 211
TABLE 163 NEW ZEALAND: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 211
TABLE 164 NEW ZEALAND: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 212
TABLE 165 NEW ZEALAND: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 166 NEW ZEALAND: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 167 NEW ZEALAND: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 213
TABLE 168 NEW ZEALAND: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 213
TABLE 169 NEW ZEALAND: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 214
TABLE 170 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 214
TABLE 171 REST OF ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 215
TABLE 172 REST OF ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 215
TABLE 173 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 215
TABLE 174 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 175 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 176 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 216
TABLE 177 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 217
TABLE 178 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 217
TABLE 179 NORTH AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 219
TABLE 180 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 220
TABLE 181 NORTH AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 220
TABLE 182 NORTH AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 220
TABLE 183 NORTH AMERICA: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 221
TABLE 184 NORTH AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 221
TABLE 185 NORTH AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 221
TABLE 186 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 222
TABLE 187 NORTH AMERICA: VETERINARY VACCINES MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 222
TABLE 188 NORTH AMERICA: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 223
TABLE 189 NUMBER OF VETERINARIANS IN US AND CANADA, 2022 224
TABLE 190 PET INDUSTRY EXPENDITURE IN US, 2018–2024 (USD BILLION) 225
TABLE 191 US: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 192 US: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 226
TABLE 193 US: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 226
TABLE 194 US: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION) 226
TABLE 195 US: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE,
2022–2029 (USD MILLION) 227
TABLE 196 US: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 227
TABLE 197 US: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 227
TABLE 198 US: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 228
TABLE 199 US: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION) 228
TABLE 200 CANADA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 229
TABLE 201 CANADA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 229
TABLE 202 CANADA: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 230
TABLE 203 CANADA: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 230
TABLE 204 CANADA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 205 CANADA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 206 CANADA: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 231
TABLE 207 CANADA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 232
TABLE 208 CANADA: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 232
TABLE 209 EUROPE: VETERINARY VACCINES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 233
TABLE 210 EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 211 EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 212 EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 234
TABLE 213 EUROPE: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 235
TABLE 214 EUROPE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 235
TABLE 215 EUROPE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 235
TABLE 216 EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 236
TABLE 217 EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 236
TABLE 218 EUROPE: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 237
TABLE 219 NUMBER OF VETERINARIANS IN EUROPE, 2022 238
TABLE 220 GERMANY: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 221 GERMANY: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 222 GERMANY: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 240
TABLE 223 GERMANY: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 240
TABLE 224 GERMANY: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 240
TABLE 225 GERMANY: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 241
TABLE 226 GERMANY: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 241
TABLE 227 GERMANY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 242
TABLE 228 GERMANY: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 242
TABLE 229 PET POPULATION IN UK, 2024 243
TABLE 230 UK: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 243
TABLE 231 UK: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 244
TABLE 232 UK: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 244
TABLE 233 UK: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION) 244
TABLE 234 UK: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE,
2022–2029 (USD MILLION) 245
TABLE 235 UK: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 245
TABLE 236 UK: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 245
TABLE 237 UK: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 246
TABLE 238 UK: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION) 246
TABLE 239 FRANCE: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 247
TABLE 240 FRANCE: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 247
TABLE 241 FRANCE: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 248
TABLE 242 FRANCE: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 248
TABLE 243 FRANCE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 244 FRANCE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 249
TABLE 245 FRANCE: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 249
TABLE 246 FRANCE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 250
TABLE 247 FRANCE: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 250
TABLE 248 ITALY: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 251
TABLE 249 ITALY: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 251
TABLE 250 ITALY: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 252
TABLE 251 ITALY: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION) 252
TABLE 252 ITALY: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 253 ITALY: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 253
TABLE 254 ITALY: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 253
TABLE 255 ITALY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 254
TABLE 256 ITALY: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION) 254
TABLE 257 SPAIN: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 255
TABLE 258 SPAIN: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 255
TABLE 259 SPAIN: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 256
TABLE 260 SPAIN: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION) 256
TABLE 261 SPAIN: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 256
TABLE 262 SPAIN: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 257
TABLE 263 SPAIN: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 257
TABLE 264 SPAIN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 258
TABLE 265 SPAIN: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 258
TABLE 266 NETHERLANDS: VETERINARY VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 259
TABLE 267 NETHERLANDS: LIVESTOCK VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 259
TABLE 268 NETHERLANDS: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 260
TABLE 269 NETHERLANDS: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 260
TABLE 270 NETHERLANDS: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 260
TABLE 271 NETHERLANDS: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 261
TABLE 272 NETHERLANDS: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 261
TABLE 273 NETHERLANDS: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 262
TABLE 274 NETHERLANDS: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 262
TABLE 275 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 263
TABLE 276 REST OF EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 263
TABLE 277 REST OF EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 264
TABLE 278 REST OF EUROPE: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 264
TABLE 279 REST OF EUROPE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 264
TABLE 280 REST OF EUROPE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 265
TABLE 281 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 265
TABLE 282 REST OF EUROPE: VETERINARY VACCINES MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 266
TABLE 283 REST OF EUROPE: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 266
TABLE 284 LATIN AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 267
TABLE 285 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 267
TABLE 286 LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 268
TABLE 287 LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 268
TABLE 288 LATIN AMERICA: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 268
TABLE 289 LATIN AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 269
TABLE 290 LATIN AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 269
TABLE 291 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 269
TABLE 292 LATIN AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 270
TABLE 293 LATIN AMERICA: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 270
TABLE 294 BRAZIL: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 272
TABLE 295 BRAZIL: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 272
TABLE 296 BRAZIL: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 272
TABLE 297 BRAZIL: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION) 273
TABLE 298 BRAZIL: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 273
TABLE 299 BRAZIL: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 273
TABLE 300 BRAZIL: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 274
TABLE 301 BRAZIL: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 274
TABLE 302 BRAZIL: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 275
TABLE 303 MEXICO: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 276
TABLE 304 MEXICO: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 276
TABLE 305 MEXICO: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 276
TABLE 306 MEXICO: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 277
TABLE 307 MEXICO: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 277
TABLE 308 MEXICO: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 277
TABLE 309 MEXICO: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 278
TABLE 310 MEXICO: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 278
TABLE 311 MEXICO: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 279
TABLE 312 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 279
TABLE 313 REST OF LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 280
TABLE 314 REST OF LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 280
TABLE 315 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 280
TABLE 316 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 281
TABLE 317 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 281
TABLE 318 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 281
TABLE 319 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 282
TABLE 320 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 282
TABLE 321 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 283
TABLE 322 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 284
TABLE 323 MIDDLE EAST & AFRICA: LIVESTOCK VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 284
TABLE 324 MIDDLE EAST & AFRICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 284
TABLE 325 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 285
TABLE 326 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 285
TABLE 327 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 285
TABLE 328 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 286
TABLE 329 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 286
TABLE 330 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 287
TABLE 331 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 288
TABLE 332 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 289
TABLE 333 GCC COUNTRIES: LIVESTOCK VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 289
TABLE 334 GCC COUNTRIES: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 289
TABLE 335 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 290
TABLE 336 GCC COUNTRIES: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 290
TABLE 337 GCC COUNTRIES: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 290
TABLE 338 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 291
TABLE 339 GCC COUNTRIES: VETERINARY VACCINES MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 291
TABLE 340 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 292
TABLE 341 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 293
TABLE 342 KINGDOM OF SAUDI ARABIA: LIVESTOCK VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 293
TABLE 343 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 293
TABLE 344 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 294
TABLE 345 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 294
TABLE 346 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 294
TABLE 347 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 295
TABLE 348 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 295
TABLE 349 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION) 296
TABLE 350 UAE: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 297
TABLE 351 UAE: LIVESTOCK VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 297
TABLE 352 UAE: COMPANION ANIMAL VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 297
TABLE 353 UAE: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION) 298
TABLE 354 UAE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE,
2022–2029 (USD MILLION) 298
TABLE 355 UAE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES,
BY TYPE, 2022–2029 (USD MILLION) 298
TABLE 356 UAE: VETERINARY VACCINES MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 299
TABLE 357 UAE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2029 (USD MILLION) 299
TABLE 358 UAE: VETERINARY VACCINES MARKET, BY END USER, 2022–2029 (USD MILLION) 300
TABLE 359 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 301
TABLE 360 REST OF GCC COUNTRIES: LIVESTOCK VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 301
TABLE 361 REST OF GCC COUNTRIES: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 301
TABLE 362 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY DISEASE,
2022–2029 (USD MILLION) 302
TABLE 363 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 302
TABLE 364 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 302
TABLE 365 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 303
TABLE 366 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 303
TABLE 367 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY END USER,
2022–2029 (USD MILLION) 304
TABLE 368 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2022–2029 (USD MILLION) 304
TABLE 369 REST OF MIDDLE EAST & AFRICA: LIVESTOCK VACCINES MARKET, BY TYPE,
2022–2029 (USD MILLION) 305
TABLE 370 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL VACCINES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 305
TABLE 371 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY DISEASE, 2022–2029 (USD MILLION) 305
TABLE 372 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022–2029 (USD MILLION) 306
TABLE 373 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022–2029 (USD MILLION) 306
TABLE 374 REST OF MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 306
TABLE 375 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 307
TABLE 376 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET,
BY END USER, 2022–2029 (USD MILLION) 307
TABLE 377 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN
VETERINARY VACCINES MARKET 308
TABLE 378 VETERINARY VACCINES MARKET: DEGREE OF COMPETITION 312
TABLE 379 VETERINARY VACCINES MARKET: REGION FOOTPRINT 317
TABLE 380 VETERINARY VACCINES MARKET: TYPE FOOTPRINT 318
TABLE 381 VETERINARY VACCINES MARKET: DISEASE FOOTPRINT 319
TABLE 382 VETERINARY VACCINES MARKET: TECHNOLOGY FOOTPRINT 320
TABLE 383 VETERINARY VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 323
TABLE 384 VETERINARY VACCINES MARKET: COMPETITIVE BENCHMARKING OF
KEY STARTUPS/SMES 323
TABLE 385 VETERINARY VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–DECEMBER 2024 326
TABLE 386 VETERINARY VACCINES MARKET: DEALS, JANUARY 2021–DECEMBER 2024 327
TABLE 387 VETERINARY VACCINES MARKET: EXPANSIONS, JANUARY 2021–DECEMBER 2024 328
TABLE 388 VETERINARY VACCINES MARKET: OTHER DEVELOPMENTS,
JANUARY 2021–DECEMBER 2024 328
TABLE 389 MERCK & CO., INC.: COMPANY OVERVIEW 329
TABLE 390 MERCK & CO., INC.: PRODUCTS OFFERED 330
TABLE 391 MERCK & CO., INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–DECEMBER 2024 333
TABLE 392 MERCK & CO., INC.: DEALS, JANUARY 2021–DECEMBER 2024 334
TABLE 393 MERCK & CO., INC.: EXPANSIONS, JANUARY 2021–DECEMBER 2024 334
TABLE 394 MERCK & CO., INC.: OTHER DEVELOPMENTS, JANUARY 2021− DECEMBER 2024 335
TABLE 395 ZOETIS: COMPANY OVERVIEW 336
TABLE 396 ZOETIS: PRODUCTS OFFERED 337
TABLE 397 ZOETIS: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024 339
TABLE 398 ZOETIS: DEALS, JANUARY 2021–DECEMBER 2024 339
TABLE 399 ZOETIS: EXPANSIONS, JANUARY 2021–DECEMBER 2024 339
TABLE 400 ZOETIS: OTHER DEVELOPMENTS, JANUARY 2021–DECEMBER 2024 340
TABLE 401 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 341
TABLE 402 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED 342
TABLE 403 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT LAUNCHES,
JANUARY 2021–DECEMBER 2024 343
TABLE 404 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS,
JANUARY 2021–DECEMBER 2024 344
TABLE 405 ELANCO: COMPANY OVERVIEW 346
TABLE 406 ELANCO: PRODUCTS OFFERED 348
TABLE 407 ELANCO: DEALS, JANUARY 2021–DECEMBER 2024 349
TABLE 408 CEVA: COMPANY OVERVIEW 350
TABLE 409 CEVA: PRODUCTS OFFERED 350
TABLE 410 CEVA: DEALS, JANUARY 2021–DECEMBER 2024 352
TABLE 411 CEVA: EXPANSIONS, JANUARY 2021–DECEMBER 2024 353
TABLE 412 VIRBAC: COMPANY OVERVIEW 354
TABLE 413 VIRBAC: PRODUCTS OFFERED 355
TABLE 414 VIRBAC: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024 356
TABLE 415 VIRBAC: DEALS, JANUARY 2021–DECEMBER 2024 357
TABLE 416 VIRBAC: EXPANSIONS, JANUARY 2021–DECEMBER 2024 357
TABLE 417 VIRBAC: OTHER DEVELOPMENTS, JANUARY 2021–DECEMBER 2024 358
TABLE 418 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY OVERVIEW 359
TABLE 419 PHIBRO ANIMAL HEALTH CORPORATION: PRODUCTS OFFERED 360
TABLE 420 HESTER BIOSCIENCES LIMITED: COMPANY OVERVIEW 362
TABLE 421 HESTER BIOSCIENCES LIMITED: PRODUCTS OFFERED 363
TABLE 422 HESTER BIOSCIENCES LIMITED: DEALS, JANUARY 2021–DECEMBER 2024 365
TABLE 423 NEOGEN CORPORATION: COMPANY OVERVIEW 366
TABLE 424 NEOGEN CORPORATION: PRODUCTS OFFERED 367
TABLE 425 NEOGEN CORPORATION: DEALS, JANUARY 2021–DECEMBER 2024 368
TABLE 426 HIPRA: COMPANY OVERVIEW 369
TABLE 427 HIPRA: PRODUCTS OFFERED 369
TABLE 428 HIPRA: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024 372
TABLE 429 BIOGÉNESIS BAGÓ: COMPANY OVERVIEW 373
TABLE 430 BIOGÉNESIS BAGÓ: PRODUCTS OFFERED 373
TABLE 431 BIOGÉNESIS BAGÓ: EXPANSIONS, JANUARY 2021–DECEMBER 2024 374
TABLE 432 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 375
TABLE 433 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: PRODUCTS OFFERED 376
TABLE 434 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: DEALS, JANUARY 2021–
DECEMBER 2024 378
TABLE 435 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: COMPANY OVERVIEW 379
TABLE 436 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: PRODUCTS OFFERED 379
TABLE 437 JINYU BIO-TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 381
TABLE 438 JINYU BIO-TECHNOLOGY CO., LTD.: PRODUCTS OFFERED 382
TABLE 439 JINYU BIO-TECHNOLOGY CO., LTD.: PRODUCT APPROVALS,
JANUARY 2021–DECEMBER 2024 384
TABLE 440 VAXXINOVA INTERNATIONAL B.V.: COMPANY OVERVIEW 385
TABLE 441 VAXXINOVA INTERNATIONAL B.V.: PRODUCTS OFFERED 386
TABLE 442 VAXXINOVA INTERNATIONAL B.V.: PRODUCT APPROVALS,
JANUARY 2021–DECEMBER 2024 387
TABLE 443 VAXXINOVA INTERNATIONAL B.V.: EXPANSIONS, JANUARY 2021–DECEMBER 2024 387
TABLE 444 ENDOVAC ANIMAL HEALTH: COMPANY OVERVIEW 388
TABLE 445 BRILLIANT BIO PHARMA: COMPANY OVERVIEW 389
TABLE 446 APTIMMUNE: COMPANY OVERVIEW 390
TABLE 447 INDIAN IMMUNOLOGICALS LTD.: COMPANY OVERVIEW 391
TABLE 448 TORIGEN PHARMACEUTICALS INC.: COMPANY OVERVIEW 392
TABLE 449 INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW 392
TABLE 450 OUROFINO ANIMAL HEALTH: COMPANY OVERVIEW 393
TABLE 451 BIOVAC LTD.: COMPANY OVERVIEW 394
TABLE 452 LABORATOIRE LCV: COMPANY OVERVIEW 395
TABLE 453 KYORITSU SEIYAKU CORPORATION: COMPANY OVERVIEW 396
LIST OF FIGURES
FIGURE 1 VETERINARY VACCINES MARKET SEGMENTATION & GEOGRAPHICAL SPREAD 34
FIGURE 2 VETERINARY VACCINES MARKET: YEARS CONSIDERED 36
FIGURE 3 VETERINARY VACCINES MARKET: RESEARCH DESIGN 38
FIGURE 4 VETERINARY VACCINES MARKET: KEY DATA FROM SECONDARY SOURCES 40
FIGURE 5 VETERINARY VACCINES MARKET: KEY PRIMARY SOURCES 40
FIGURE 6 VETERINARY VACCINES MARKET: KEY DATA FROM PRIMARY SOURCES 41
FIGURE 7 VETERINARY VACCINES MARKET: KEY INDUSTRY INSIGHTS 42
FIGURE 8 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 42
FIGURE 9 BREAKDOWN OF PRIMARIES (SUPPLY-SIDE PARTICIPANTS): BY COMPANY TYPE, DESIGNATION, AND REGION 43
FIGURE 10 BREAKDOWN OF PRIMARIES (DEMAND-SIDE PARTICIPANTS): BY END USER, DESIGNATION, AND REGION 43
FIGURE 11 VETERINARY VACCINES MARKET: SUPPLY-SIDE MARKET SIZE
ESTIMATION PROCESS 44
FIGURE 12 VETERINARY VACCINES MARKET: REVENUE SHARE ILLUSTRATION
FOR ZOETIS (2023) 45
FIGURE 13 VETERINARY VACCINES MARKET: TOTAL REVENUE ANALYSIS (2023) 45
FIGURE 14 VETERINARY VACCINES MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 47
FIGURE 15 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS 47
FIGURE 16 VETERINARY VACCINES MARKET: TOP-DOWN APPROACH 48
FIGURE 17 VETERINARY VACCINES MARKET: DATA TRIANGULATION 49
FIGURE 18 VETERINARY VACCINES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 52
FIGURE 19 VETERINARY VACCINES MARKET, BY DISEASE, 2024 VS. 2029 (USD MILLION) 53
FIGURE 20 VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION) 53
FIGURE 21 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2024 VS. 2029 (USD MILLION) 54
FIGURE 22 VETERINARY VACCINES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 55
FIGURE 23 VETERINARY VACCINES MARKET: REGIONAL SNAPSHOT 56
FIGURE 24 INCREASING COMPANION ANIMAL POPULATION AND RISING INCIDENCE OF ZOONOTIC DISEASES TO DRIVE MARKET 57
FIGURE 25 CHINA AND LIVE ATTENUATED VACCINES COMMANDED LARGEST
MARKET SHARE IN 2023 58
FIGURE 26 CHINA TO WITNESS HIGHEST CAGR FROM 2024 TO 2029 59
FIGURE 27 VETERINARY VACCINES MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 60
FIGURE 28 PET POPULATION IN MAJOR MARKETS IN 2022 (MILLION) 61
FIGURE 29 VETERINARY VACCINES MARKET: TRENDS/DISRUPTIONS IMPACTING
CUSTOMER’S BUSINESS 71
FIGURE 30 VETERINARY VACCINES MARKET: SUPPLY CHAIN ANALYSIS 73
FIGURE 31 VETERINARY VACCINES MARKET: VALUE CHAIN ANALYSIS 74
FIGURE 32 VETERINARY VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS 76
FIGURE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER 78
FIGURE 34 KEY BUYING CRITERIA FOR END USERS 79
FIGURE 35 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR VETERINARY VACCINE PATENTS (JANUARY 2014–NOVEMBER 2024) 87
FIGURE 36 AVERAGE SELLING PRICE OF LIVESTOCK VACCINES, BY KEY PLAYER, 2023 (USD) 90
FIGURE 37 AVERAGE SELLING PRICE OF PORCINE VACCINES, BY KEY PLAYER, 2023 (USD) 91
FIGURE 38 VETERINARY VACCINES MARKET: ECOSYSTEM ANALYSIS 94
FIGURE 39 VETERINARY VACCINES MARKET: NUMBER OF DEALS AND VALUE OF INVESTMENTS, 2018–2022 99
FIGURE 40 ASIA PACIFIC: VETERINARY VACCINES MARKET SNAPSHOT 183
FIGURE 41 CAT POPULATION ACROSS KEY ASIA PACIFIC COUNTRIES (2024) 188
FIGURE 42 EXPECTED GROWTH IN NUMBER OF VETERINARIANS IN NORTH AMERICA 218
FIGURE 43 NORTH AMERICA: VETERINARY VACCINES MARKET SNAPSHOT 219
FIGURE 44 PET (DOG AND CAT) POPULATION IN US AND CANADA (2022) 224
FIGURE 45 PET (DOG AND CAT) POPULATION IN KEY EUROPEAN COUNTRIES (2022) 238
FIGURE 46 PET (DOG AND CAT) POPULATION IN KEY LATIN AMERICAN COUNTRIES (2022) 271
FIGURE 47 CAT POPULATION IN MIDDLE EASTERN & AFRICAN COUNTRIES (2022) 288
FIGURE 48 VETERINARY VACCINES MARKET: REVENUE ANALYSIS OF
TOP FIVE PLAYERS (2019–2023) 311
FIGURE 49 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY
VACCINES MARKET (2023) 312
FIGURE 50 VETERINARY VACCINES MARKET: RANKING OF KEY MARKET PLAYERS (2023) 313
FIGURE 51 VETERINARY VACCINES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 315
FIGURE 52 VETERINARY VACCINES MARKET: COMPANY FOOTPRINT 316
FIGURE 53 VETERINARY VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 322
FIGURE 54 VETERINARY VACCINES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 324
FIGURE 55 VETERINARY VACCINES MARKET: R&D EXPENDITURE OF
KEY PLAYERS (2021–2023) 325
FIGURE 56 EV/EBITDA OF KEY VENDORS 325
FIGURE 57 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 326
FIGURE 58 MERCK & CO., INC.: COMPANY SNAPSHOT 330
FIGURE 59 ZOETIS: COMPANY SNAPSHOT 337
FIGURE 60 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT 342
FIGURE 61 ELANCO: COMPANY SNAPSHOT 347
FIGURE 62 VIRBAC: COMPANY SNAPSHOT 355
FIGURE 63 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT 360
FIGURE 64 HESTER BIOSCIENCES LIMITED: COMPANY SNAPSHOT 363
FIGURE 65 NEOGEN CORPORATION: COMPANY SNAPSHOT 367
FIGURE 66 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: COMPANY SNAPSHOT 376
FIGURE 67 JINYU BIO-TECHNOLOGY CO., LTD.: COMPANY SNAPSHOT 381
」。
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11